What a difference 12 months makes. Last year’s forecast for the top 10 drugs of 2021 did not even include two of the year’s eventual biggest sellers, the COVID-19 vaccines Comirnaty (tozinameran; Pfizer/BioNTech) and Spikevax (Moderna). The omission of two of the fastest-selling drugs in the pharmaceutical industry’s history was largely down to their emergency use authorizations (EUAs) in December 2020 and uncertainty around manufacturing capacity to deliver promised doses, making forecasting sales difficult.

Enjoying our latest content?
Log in or create an account to continue

  • Access the most recent journalism from Nature's award-winning team
  • Explore the latest features & opinion covering groundbreaking research
Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD